|
|
 |
|
Viewing report
|
|
|
|
Currently Druggable in Colorectal Cancer: A Drug Target Competitive Analysis
Bioseeker, Dec 2008, Pages: 299
Not surprisingly, an increasing number of companies have turned their attention to the cancer targeted therapy market, undoubtedly trying to emulate the blockbuster status that several brands have already achieved.
This report aims to analyze the current and future potential of colorectal cancer pipeline by examining key fundamentals across the entire pipeline of drug candidates. the author has identified three fundamental dimensions to outline the competitive landscape within the pharmaceutical industry; compound type, therapy area and target type.
This report is written for you to identify your competition and understand which targeting strategies are at work within colorectal cancer drug development. It allows you to pin-point which competitors drugs’ clinical out-come may have bearing on your own drug development and who are developing sequels to successful drugs. This report also helps you to locate white-spots in the competitive landscape, giving you little or no competition. Conversely it may reveal unexpected competition for you.
Drug targets are the critical link between drugs and their role in the treatment of medical disorders. BioSeeker has surveyed the colorectal cancer field and identified 120 drug targets belonging to 156 drugs. This report, Currently Druggable in Colorectal Cancer: A Drug Target Competitive Analysis is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of colorectal cancer drugs.
In the report, the author reports on 105 unique drug target combinations, each comprised of a different collection or mix of individually defined targets, for 156 colorectal cancer drugs. The highest degree of distinctiveness among the cancer drugs is achieved by sorting each of them according to drug target mix, compound type and R&D approach. At the same time we are also identifying peer groups of drugs, that is, drugs we consider suitable for head-to-head comparison during drug development.
To fuel the scientific and competitive thinking, the author opens the gate into the presence and relevance of protein-protein interactions between identified targets of colorectal cancer drugs. No less than 231 target-target interactions were recognized among and between 87 of the 120 included colorectal cancer drug targets.
Why You Should Own Your Own Copy of this Report:
- 300 pages, with more than 50 different tables and figures. Includes more than 1,000 active links to drug target related resources on the Internet
- A 156 colorectal cancer drugs analysis, under development by 95 investigators
- 120 unique, in-depth, drug target validating profiles, highlighting twelve themes about the drug target, i.e. protein-protein interaction with other colorectal cancer drug targets, pursued cancer indications, drugs under development, presence in the Cancer Genome Project etc.
- A unique drug target combination breakdown of colorectal cancer drugs into R&D approaches
- Unique drug-protein target interactome- and protein-protein interactome of drug targets analysis
- Pathway profiling of colorectal cancer drug targets
- Compound strategies based on sub-cellular localization of drug targets
- Expression levels of identified drug targets in malignant colorectal cancer tissue
- Structure based drug design in colorectal cancer
- Pin-point which competitor drugs’ clinical out-come may have bearing on your own drug development
- Who are working on sequels to blockbuster drugs?
- Locate white-spots in the competitive landscape, giving you little or no competition
In all, this report is a serious reference for any professional interested in the development of oncology drug targets and the selection/validation of targeting strategies.
Customers who bought this item also bought
Colorectal Cancer Drug Pipeline Update 2008
Triple Analysis: The Drug Target Atlas of Apoptopic Drugs in Oncology and Special Focus on Lung Cancer and Melanoma
Triple Analysis: The Drug Target Atlas of Apoptopic Drugs in Oncology and Special Focus on Breast and Prostate Cancer
GPCR - Drug Targets
Cancer Drug Resistance
The Drug Target Atlas of Protein Kinase Inhibitors in Oncology
Drug Targets for Breast Cancer
Antibody Drug Targets and Focus on Breast & Prostate Cancer
Drugs of Tomorrow 2002: Colorectal Cancer
Drug Delivery in Cancer - Technologies, Markets and Companies
Currently Druggable in Prostate Cancer: A Drug Target Competitive Analysis
Cancer Drug Discoveries: What the Future Holds: Colorectal Cancer Chapter
|
|
|
|
